Literature DB >> 26830665

Prognostic implication of relative regional strain ratio in cardiac amyloidosis.

Alpana Senapati1, Brett W Sperry2, Justin L Grodin2, Kenya Kusunose3, Paaladinesh Thavendiranathan4, Wael Jaber2, Patrick Collier2, Mazen Hanna2, Zoran B Popovic, Dermot Phelan2.   

Abstract

OBJECTIVE: Cardiac amyloidosis (CA) is a rapidly progressive disease that portends poor prognosis. Our objective was to evaluate the prognostic impact of relative regional strain ratio (RRSR, a measure of the relative apical sparing of longitudinal strain (LS)) in CA.
METHODS: This is a retrospective study evaluating 97 patients with CA from 2004 to 2013. Patients were included if they met criteria for CA based on endomyocardial biopsy or advanced imaging criteria coupled with either extracardiac biopsy or genetic analysis. Baseline clinical and imaging data were collected and compared between light-chain amyloidosis (AL) (n=59) and transthyretin amyloidosis (ATTR) (n=38) subtypes. RRSR was defined as the average apical LS divided by the sum of the average mid and basal LS values. A Cox proportional hazards model was used to assess the effects of clinical and echocardiographic characteristics, including RRSR, on the outcome of time to death or heart transplantation.
RESULTS: Despite younger age, the AL subtype had a statistically significant association with the composite outcome as compared with ATTR (p=0.022). Log-transformed RRSR was independently associated with the composite outcome at 5 years (HR 2.45 (1.36 to 4.40), p=0.003). Patients with low ejection fraction and high RRSR had the worst prognosis. In multivariable analysis, RRSR remained predictive of the primary outcome (p=0.018). Addition of covariates related to systolic function (global LS and ejection fraction) to the model attenuated this effect.
CONCLUSIONS: High RRSR is adversely prognostic in patients with cardiac amyloid. This novel tool is both diagnostic and prognostic and may have implications in management and suitability for treatment. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Mesh:

Year:  2016        PMID: 26830665     DOI: 10.1136/heartjnl-2015-308657

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  35 in total

Review 1.  Advances in Treatment of Cardiac Amyloid.

Authors:  Cherie N Dahm; R Frank Cornell; Daniel J Lenihan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-04-07

2.  Pattern of myocardial 99mTc-HMDP uptake and impact on myocardial function in patients with transthyretin cardiac amyloidosis.

Authors:  Sarah Pradel; Stéphanie Brun; Gérard Victor; Pierre Pascal; Pauline Fournier; David Ribes; Yoan Lavie-Badie; Michel Galinier; Didier Carrié; Isabelle Berry; Olivier Lairez
Journal:  J Nucl Cardiol       Date:  2018-06-07       Impact factor: 5.952

Review 3.  Role of Imaging in Evaluating Infiltrative Heart Disease.

Authors:  Sanjay Divakaran; Avinainder Singh; Bradley Collins; Tomas Vita; Rodney H Falk; Marcelo F Di Carli; Ron Blankstein
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-01

4.  Predictors of survival stratification in patients with wild-type cardiac amyloidosis.

Authors:  F Aus dem Siepen; R Bauer; A Voss; S Hein; M Aurich; J Riffel; D Mereles; C Röcken; S J Buss; H A Katus; Arnt V Kristen
Journal:  Clin Res Cardiol       Date:  2017-09-27       Impact factor: 5.460

Review 5.  Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment.

Authors:  Omar K Siddiqi; Frederick L Ruberg
Journal:  Trends Cardiovasc Med       Date:  2017-07-13       Impact factor: 6.677

6.  ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging.

Authors:  Sharmila Dorbala; Yukio Ando; Sabahat Bokhari; Angela Dispenzieri; Rodney H Falk; Victor A Ferrari; Marianna Fontana; Olivier Gheysens; Julian D Gillmore; Andor W J M Glaudemans; Mazen A Hanna; Bouke P C Hazenberg; Arnt V Kristen; Raymond Y Kwong; Mathew S Maurer; Giampaolo Merlini; Edward J Miller; James C Moon; Venkatesh L Murthy; C Cristina Quarta; Claudio Rapezzi; Frederick L Ruberg; Sanjiv J Shah; Riemer H J A Slart; Hein J Verberne; Jamieson M Bourque
Journal:  J Nucl Cardiol       Date:  2019-12       Impact factor: 5.952

7.  Subclinical myocardial disease in patients with primary hyperoxaluria and preserved left ventricular ejection fraction: a two-dimensional speckle-tracking imaging study.

Authors:  Ruth Lagies; Floris E A Udink Ten Cate; Markus Feldkötter; Bodo B Beck; Narayanswami Sreeram; Bernd Hoppe; Ulrike Herberg
Journal:  Pediatr Nephrol       Date:  2019-08-22       Impact factor: 3.714

Review 8.  How to Image Cardiac Amyloidosis: A Practical Approach.

Authors:  Sharmila Dorbala; Sarah Cuddy; Rodney H Falk
Journal:  JACC Cardiovasc Imaging       Date:  2019-10-11

Review 9.  Recent advances in the noninvasive strategies of cardiac amyloidosis.

Authors:  Lei Zhao; Quan Fang
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

Review 10.  Clinical Applications of Echo Strain Imaging: a Current Appraisal.

Authors:  Agostina M Fava; Dane Meredith; Milind Y Desai
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.